Detalhe da pesquisa
1.
Polypill with or without Aspirin in Persons without Cardiovascular Disease.
N Engl J Med
; 384(3): 216-228, 2021 01 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-33186492
2.
Glycemic Index, Glycemic Load, and Cardiovascular Disease and Mortality.
N Engl J Med
; 384(14): 1312-1322, 2021 04 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-33626252
3.
Development of semi-quantitative urinary sodium test strip.
Biotechnol Appl Biochem
; 70(2): 603-612, 2023 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-35830743
4.
Lowering cholesterol, blood pressure, or both to prevent cardiovascular events: results of 8.7 years of follow-up of Heart Outcomes Evaluation Prevention (HOPE)-3 study participants.
Eur Heart J
; 42(31): 2995-3007, 2021 08 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-33963372
5.
Antihypertensives and Statin Therapy for Primary Stroke Prevention: A Secondary Analysis of the HOPE-3 Trial.
Stroke
; 52(8): 2494-2501, 2021 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-33985364
6.
Modifiable risk factors, cardiovascular disease, and mortality in 155â722 individuals from 21 high-income, middle-income, and low-income countries (PURE): a prospective cohort study.
Lancet
; 395(10226): 795-808, 2020 03 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-31492503
7.
Renal Impairment and Risk of Acute Stroke: The INTERSTROKE Study.
Neuroepidemiology
; 55(3): 206-215, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-33951632
8.
High prevalence of dyslipidaemia subtypes and their associated personal and clinical attributes in Malaysian adults: the REDISCOVER study.
BMC Cardiovasc Disord
; 21(1): 149, 2021 03 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-33757445
9.
A community-based comprehensive intervention to reduce cardiovascular risk in hypertension (HOPE 4): a cluster-randomised controlled trial.
Lancet
; 394(10205): 1231-1242, 2019 10 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-31488369
10.
Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease.
N Engl J Med
; 377(14): 1319-1330, 2017 10 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-28844192
11.
Pantoprazole to Prevent Gastroduodenal Events in Patients Receiving Rivaroxaban and/or Aspirin in a Randomized, Double-Blind, Placebo-Controlled Trial.
Gastroenterology
; 157(2): 403-412.e5, 2019 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-31054846
12.
Safety of Proton Pump Inhibitors Based on a Large, Multi-Year, Randomized Trial of Patients Receiving Rivaroxaban or Aspirin.
Gastroenterology
; 157(3): 682-691.e2, 2019 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-31152740
13.
Association of estimated sleep duration and naps with mortality and cardiovascular events: a study of 116 632 people from 21 countries.
Eur Heart J
; 40(20): 1620-1629, 2019 05 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-30517670
14.
Urinary sodium excretion, blood pressure, cardiovascular disease, and mortality: a community-level prospective epidemiological cohort study.
Lancet
; 392(10146): 496-506, 2018 08 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-30129465
15.
Association of dairy intake with cardiovascular disease and mortality in 21 countries from five continents (PURE): a prospective cohort study.
Lancet
; 392(10161): 2288-2297, 2018 11 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-30217460
16.
Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial.
Lancet
; 391(10117): 205-218, 2018 01 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-29132879
17.
Practice patterns and outcomes after stroke across countries at different economic levels (INTERSTROKE): an international observational study.
Lancet
; 391(10134): 2019-2027, 2018 05 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-29864018
18.
Blood-Pressure Lowering in Intermediate-Risk Persons without Cardiovascular Disease.
N Engl J Med
; 374(21): 2009-20, 2016 May 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-27041480
19.
Blood-Pressure and Cholesterol Lowering in Persons without Cardiovascular Disease.
N Engl J Med
; 374(21): 2032-43, 2016 May 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-27039945
20.
Cholesterol Lowering in Intermediate-Risk Persons without Cardiovascular Disease.
N Engl J Med
; 374(21): 2021-31, 2016 May 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-27040132